Last reviewed · How we verify

NCT04478591: WOC

The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis

Completed Last updated 28 September 2021
What this trial tests

trial testing Questionnaires in Multiple Sclerosis in 117 participants. Completed in 1 May 2021.

Timeline
12 May 2020
Primary endpoint
1 April 2021
1 May 2021

Quick facts

Lead sponsorAmsterdam UMC, location VUmc
StatusCompleted
Study typeOBSERVATIONAL
Enrollment117
Start date12 May 2020
Primary completion1 April 2021
Estimated completion1 May 2021
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Amsterdam UMC, location VUmc — full company profile →

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this research is to study the prevalence of the wearing-off effect and possible risk factors for wearing-off symptoms in patients with multiple sclerosis using ocrelizumab with the use of questionnaires. Furthermore, the goal is to study whether patients receiving extended dosing of ocrelizumab experience more wearing-off symptoms or adverse events in general. Finally, we would like to extend knowledge on wearing-off symptoms in general.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A, O'Brien SM, Sweeney ML, Fox EJ, et al · · 2021 · cited 37× · PMID 34370283 · DOI 10.1007/s40263-021-00843-8
  2. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES, Pretzsch R, Weber MS. · · 2021 · cited 22× · PMID 33880738 · DOI 10.1007/s13311-021-01048-z

Verify or expand the search:

Other trials of Questionnaires

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Amsterdam UMC, location VUmc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04478591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing